Kamada (KMDA) Total Liabilities (2012 - 2026)
Kamada (KMDA) posted quarterly Total Liabilities of $383.0 million for Q1 2026, up 2.11% year-on-year from $375.1 million in Q1 2025, and up 1.14% on a QoQ basis from $378.7 million in Q4 2025.
Kamada (KMDA) Total Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Total Liabilities for 13 consecutive years, with $383.0 million the latest figure, recorded in Q1 2026.
- Quarterly Total Liabilities rose 2.11% year-over-year to $383.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383.0 million (up 2.11% YoY) and the FY2025 annual result came in at $378.7 million, up 1.73% from the prior year.
- Total Liabilities grew to $383.0 million in Q1 2026 per KMDA's latest filing, from $378.7 million in the prior quarter.
- Over the last five years, Total Liabilities for KMDA reached as high as $354.9 billion in Q4 2023 and fell as low as $303.1 million in Q1 2022.
- A 5-year average of $41.0 billion and a median of $351.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities soared 109989.99% — and 2024, when it tumbled 99.9%.
- Year by year, Total Liabilities stood at $322.4 million in 2022, then surged by 109989.99% to $354.9 billion in 2023, then tumbled by 99.9% to $372.3 million in 2024, then advanced by 1.73% to $378.7 million in 2025, then advanced by 1.14% to $383.0 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $383.0 million, $378.7 million, and $377.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.48 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 31.81 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.92 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 51.53 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 813.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 22.18 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.50 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.72 Bn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 383.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 383.02 Mn |
| Dec 31, 2025 | 378.71 Mn |
| Sep 30, 2025 | 377.21 Mn |
| Jun 30, 2025 | 368.17 Mn |
| Mar 31, 2025 | 375.11 Mn |
| Dec 31, 2024 | 372.26 Mn |
| Sep 30, 2024 | 351.21 Mn |
| Jun 30, 2024 | 351.04 Mn |
| Mar 31, 2024 | 343.17 Mn |
| Dec 31, 2023 | 354.91 Bn |
| Sep 30, 2023 | 337.06 Bn |
| Jun 30, 2023 | 314.39 Mn |
| Mar 31, 2023 | 316.80 Mn |
| Dec 31, 2022 | 322.38 Mn |
| Sep 30, 2022 | 319.64 Mn |
| Jun 30, 2022 | 304.14 Mn |
| Mar 31, 2022 | 303.10 Mn |
| Dec 31, 2021 | 318.67 Mn |
| Sep 30, 2021 | 216.53 Mn |
| Jun 30, 2021 | 216.35 Mn |